Ionis Pharmaceuticals Inc. diskutieren
Ionis Pharmaceuticals Inc.
WKN: A2ACMZ / Symbol: IONS / Name: Ionis Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
51,02 €
-8,18 %
Ionis Pharmaceuticals (IONS) had its price target raised by Needham & Company LLC from $103.00 to $105.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target raised by Barclays PLC from $95.00 to $106.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target raised by Bank of America Corporation from $100.00 to $111.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target lowered by TD Cowen from $110.00 to $108.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target raised by HC Wainwright from $120.00 to $125.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target raised by Royal Bank Of Canada from $95.00 to $100.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by TD Cowen. They now have a $108.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target raised by Leerink Partners from $114.00 to $122.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target raised by HC Wainwright from $125.00 to $130.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target raised by Leerink Partners from $122.00 to $129.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target lowered by Needham & Company LLC from $105.00 to $86.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target lowered by Canaccord Genuity Group Inc. from $110.00 to $95.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target lowered by Barclays PLC from $115.00 to $90.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target lowered by Morgan Stanley from $130.00 to $110.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (IONS) had its price target lowered by HC Wainwright from $130.00 to $125.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Neueste Beiträge
DA_Davidson in Agco Corp. diskutieren